Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
new york blog main
new york top stories
5
×
akcea therapeutics
alnylam pharmaceuticals
boston top stories
clinical trials
drugs
inotersen
national top stories
patisiran
san diego blog main
san diego top stories
tafamidis
boston
fda
hereditary transthyretin amyloidosis
onpattro
pfizer
rna interference
biotech
new york
regeneron pharmaceuticals
san francisco blog main
san francisco top stories
vyndaqel
alirocumab
amgen
andrew fire
anylam pharmaceuticals
barry greene
boston university
cardiomyopathy
craig mello
dan ollendorf
european medicines agency
evercore isi
evolocumab
What
alnylam
5
×
drug
fda
medicine
rna
ago
approved
medicines
patients
pharmaceuticals
rnai
uses
afternoon
akcea
alnylam’s
amyloidosis
approve
approves
attr
available
awaits
based
battle
biological
cells
cholesterol
crossed
data
debilitating
decades
decision
discovered
disease
ema
employ
europe
evidence
fingers
follows
friday
Language
Current search:
alnylam
×
" new york top stories "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision